SCHEMBL7969595

SCHEMBL7969595

Cc1cc(C(C)(C)C)cc(C)c1CC#N

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1D P28221 6/20 0.50
HTR1B P28222 4/20 0.46
POLB P06746 2/20 0.41
TSHR P16473 3/20 0.39
HTR1A P08908 2/20 0.39
ADRA2A P08913 2/20 0.39
ADRA2B P18089 2/20 0.39
ADRA2C P18825 2/20 0.39
LMNA P02545 2/20 0.39
TP53 P04637 1/20 0.39
CHRM2 P08172 1/20 0.39
CYP2D6 P10635 1/20 0.39
CHRM1 P11229 1/20 0.39
DRD2 P14416 1/20 0.39
CHRM3 P20309 1/20 0.39
ADRA1D P25100 1/20 0.39
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
MAPK1 P28482 1/20 0.39
ADRA1A P35348 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1022724 0.79 ATM (0.38) HTR1DHTR1BPOLBTSHRLMNA
SCHEMBL954302 0.76 HTT (0.32) ATM
SCHEMBL5728741 0.76 CYP2A6 (0.33) TSHRLMNAMAPTATMMEN1
SCHEMBL11860918 0.76 CYP3A4 (0.41) CHRM1ADRA1AHTR2BCYP3A4ATM
SCHEMBL9248479 0.76 GABRA1 (0.41) HTR1DHTR1BPOLBMAPTGABRA1
SCHEMBL7982969 0.76 CSNK2A1 (0.37) HTR1DHTR1BATM
SCHEMBL3255126 0.75 PGK1 (0.40) HTR1D
SCHEMBL4399868 0.74 TACR1 (0.40) HTR1DHTR1BPOLBTSHRGABRA1
SCHEMBL7969434 0.74 HTR1D (0.43) HTR1DHTR1BPOLBTSHRADRA2A
SCHEMBL5728530 0.72 ALDH1A1 (0.40) POLBTSHRLMNAMAPK1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4709392-A1 COMBINATION THERAPY GLUCOCORTICOIDS AND GINSENOSIDE Fytagoras B.V. (NL) 2026-03-18 EP claimed
WO-2024232756-A1 COMBINATION THERAPY GLUCOCORTICOIDS AND GINSENOSIDE FYTAGORAS B.V. (NL) 2024-11-14 WO claimed
CN-115109787-B Glycosyltransferase gene and application thereof in preparation of pseudo-ginseng/ginsenoside 广西科学院 2023-07-14 CN claimed
US-20220400670-A1 PROTOPANAXATRIOL (PPT)-TYPE COMPOUNDS AS ACTIVE INGREDIENTS IN INSECTICIDE PRODUCTS STOCKTON (ISRAEL) LTD. (IL) 2022-12-22 US claimed
CN-115109787-A Group of glycosyltransferase genes and application thereof in preparation of panax notoginseng/ginsenoside 广西科学院 2022-09-27 CN claimed
CN-122075502-A Compound preparation for treating vascular dementia and preparation method thereof 2026-05-26 CN disclosed
EP-4709392-A1 COMBINATION THERAPY GLUCOCORTICOIDS AND GINSENOSIDE Fytagoras B.V. (NL) 2026-03-18 EP disclosed
CN-121466152-A Application of ginseng oil body in preparation of medicines for preventing and/or treating colonitis 长春中医药大学附属医院(吉林省中医院) 2026-02-06 CN disclosed
EP-4043560-B1 GROUP OF GLYCOSYLTRANSFERASES AND USE THEREOF GSYNBIOT SHANGHAI CO LTD (CN) 2025-08-13 EP disclosed
US-12370205-B2 Composition for preventing or treating fine dust-induced respiratory disease comprising mixture (RGX-365) comprising ginsenosides RG2, RG4, RG6 and RH1, as active ingredient, and preparation method thereof AREZ CO., LTD. (KR) 2025-07-29 US disclosed
CN-120137932-A BS-YjiC mutant for conversion generation of ginsenoside and application thereof 西北大学 2025-06-13 CN disclosed
CN-120114392-A Ginsenoside liposome and preparation method and application thereof 山东铂源生物医药有限公司 2025-06-10 CN disclosed
EP-3985110-A1 GROUP OF GLYCOSYLTRANSFERASES AND USE THEREOF CAS Center for Excellence in Molecular Plant Sciences (CN) 2022-04-20 EP disclosed
CN-109234347-B Method for converting protopanaxatriol saponin to obtain C25-OH derivative 长春中医药大学 2022-03-01 CN disclosed
CN-114025770-A Pharmaceutical composition for preventing alopecia or promoting hair growth comprising ginsenoside Rg4 or mixture of ginsenoside Rg2, Rg4, Rg6 and RH1 (RGX 365) AREZ株式会社 2022-02-08 CN disclosed
US-6288101-B1 ADMINISTERING COMPOUNDS SUCH AS 2,6-DIMETHYL-4-ISOPROPYLBENZALDEHYDE TO TREAT INDICATIONS WHERE STIMULATION OF SUBTYPES OF THE SEROTONIN RECEPTOR IS IMPLICATED, SUCH AS MIGRAINES VIRGINIA COMMONWEALTH UNIVERSITY 2001-09-11 US disclosed
US-6124338-A TREATING MIGRAINE HEADACHE VIRGINIA COMMONWEALTH UNIVERSITY (US) 2000-09-26 US disclosed
US-6048862-A Benzylamidine derivatives with serotonin receptor binding activity VIRGINIA COMMONWEALTH UNIVERSITY (US) 2000-04-11 US disclosed
US-5969137-A TREATMENT OF NERVOUS SYSTEM DISORDERS VIRGINIA COMMONWEALTH UNIVERSITY (US) 1999-10-19 US disclosed
WO-1998012183-A1 IMIDAZOLES WITH SEROTONIN RECEPTOR BINDING ACTIVITY ALLELIX BIOPHARMACEUTICALS INC. (CA) 1998-03-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220400670-A1 PROTOPANAXATRIOL (PPT)-TYPE COMPOUNDS AS ACTIVE INGREDIENTS IN INSECTICIDE PRODUCTS PPT1, TPP2, PTMA HTR1D 3508/4885HTR1B 3117/4885POLB 4306/4885
US-12370205-B2 Composition for preventing or treating fine dust-induced respiratory disease comprising mixture (RGX-365) comprising ginsenosides RG2, RG4, RG6 and RH1, as active ingredient, and preparation method thereof RDX, IL4, IL33 HTR1D 4208/4885HTR1B 4597/4885POLB 4424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.